FibroGen, Inc. (LON:0IL8)

Market Cap	21.02M
Revenue (ttm)	5.41M
Net Income (ttm)	-7.75M
Shares Out	n/a
EPS (ttm)	-1.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	659
Average Volume	628
Open	6.90
Previous Close	7.05
Day's Range	6.88 - 7.00
52-Week Range	5.97 - 24.25
Beta	n/a
RSI	41.45
Earnings Date	Aug 4, 2025

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 a...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1993
• Employees: 225
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IL8

Financial Performance

In 2024, FibroGen's revenue was $29.62 million, a decrease of -36.71% compared to the previous year's $46.80 million. Losses were -$47.58 million, -83.26% less than in 2023.

Financial numbers in USD